European Journal of Cancer

Article	Citations
Editorial Board	415
84 (PB072): Discovery and characterization of potent inhibitors of the RNA editing enzyme ADAR1	250
387 (PB375): Tumor adaptation to PI3K inhibition and its stability increases as a function of time and is overcome by combined inhibiting Bcl2 family proteins	224
405 (PB393): A combination of AURK inhibitor and HDAC inhibitor can restrain Anaplastic Thyroid Cancer aggressiveness: a drug repurposing story	218
250 (PB238): In Vivo Pharmacokinetics, Pharmacodynamics and Anti-tumour Efficacy of EXS74539: A Novel, Reversible LSD1 Inhibitor for Acute Myeloid Leukaemia	182
213 (PB201): MYC Inhibition by OMO-103 Reprograms Tumor Immunity and Enhances Immunotherapy Efficacy in KRAS Mutant NSCLC	175
277 (PB265): Comparative analysis of immune responses in a 3D ex vivo patient tissue platform across diverse cancer types	154
417 (PB405): Exploring Synthetic Lethality and novel drug combinations in Patient-Derived Cells	145
272 (PB260): Establishment and evaluation of radioresistant models from patient derived tissue	145
441 (PB429): GRC 70267, a novel first-generation small molecule degrader of IRAK-M with anti-tumor activity	130
210 (PB198): KRASmulti inhibition and checkpoint targeting therapy show strong combination potential in KRAS wild-type and KRASG12V-driven syngeneic mouse models of pancreatic cancer	130
334 (PB322): PARP1 inhibitor resistant cell line generation and DDR cell panel development	129
310 (PB298): Synergistic Anti-Tumor Effects of the Novel HDAC Inhibitor, ABT-301, with Immune Checkpoint Inhibitors in Colorectal Cancer Through Regulation of Immune Response and Anti-Angiogenesis	127
Prognostic value of patient-reported outcomes in advanced or metastatic melanoma patients treated with immunotherapy: Findings from the CheckMate-067 study	116
A-222 Flow cytometry of skin biopsies in CTCL patients during Mogamulizumab treatment	115
A-262 Targeting the hyperactive STAT3/5 Pathway in Cutaneous T-Cell Lymphoma: superior efficacy of multi-kinase inhibitor IQDMA over conventional PUVA therapy	107
A-175 Toward patient-tailored immunotherapy: targeting the TCR idiotype of clonal Sézary lymphomas	101
A-288 Retrospective Clinicopathological Comparative Study between Hypopigmented Mycosis Fungoides and Pityriasis Lichenoides Chronica	98
A-246 Extranodal natural killer/T-cell lymphoma, nasal-type, with extranasal cutaneous presentation - report of 3 cases	98
363 (PB351): Ferrous Iron Reactive (FIRE) delivery of diagnostic or therapeutic agents	92
306 (PB294): OMX-0407 a spectrum selective kinase inhibitor shows preclinical and clinical efficacy in Angiosarcoma, an indication of high unmet medical need	88
71 (PB059): The efficacy and safety of a selective PARP1 inhibitor ACE-86225106 in patients with advanced solid tumors: preliminary results from a first-inhuman phase 1/2 study	86
Prognostic stratification ability of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy	82
Editorial Board	79
Response to Letter Re: “A randomized trial of patient navigation with symptom-monitoring in advanced lung cancer”	79

Re: “Evolution of low HER2 expression between early and advanced-stage breast cancer”	77
Characterization of KRAS-driven NSCLC cell lines with diverse mutational landscape and assessment of their response to MYC inhibition	76
Real world evidence from a Breast Screening pilot for the underprivileged: Experiences from Bruhat Bengaluru Mahanagara Palike hospitals	75
Large genome rearrangement of BRCA1/2 in BRCA mutation negative ovarian cancer patients	75
Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy	72
Impact of an Online Educational Activity on Oncologists’ Knowledge and Competence Regrading the Optimal Use of Adjuvant Treatment in Breast Cancer	70
Interactions between BRD4 short, LOXL2, and MED1 drive cell cycle transcription in triple-negative breast cancer	68
Local recurrence of breast cancer after mastectomy. Impact of residual tissue in cancer follow-up	67
The ULK1 inhibitor ENV-201 impairs tumor growth in KRAS-driven flank xenografts as a single agent and in combination with the KRAS inhibitor adagrasib	66
Interobserver variation in the assessment of HER2 low expression in breast cancer: can we improve by adjusting criteria? An international interobserver study	66
Triple negative breast cancers: Rising menace in the developing world and treatment challenges	65
Efficiency of textile photodynamic therapy for mycosis fungoides	63
Gene expression-based prediction of pazopanib efficacy in sarcoma	61
The Punjab breast cancer AI-digital project: Implementing Artificial Intelligence-based triaging at scale for population-level screening of breast cancer	61
The Sponsor Acknowledgment and Introduction	60
Non-clinical identification and characterization of KRAS G12D inhibitors	60
Discovery of Essential microRNA in Prostate Cancer Cells	60
Unexpectedly high seroprevalance of Kaposi's sarcoma-associated herpesvirus (HHV-8) in patients with stage IV melanoma	59
Ichthyosis associated with immune checkpoint blockade therapy: A novel cutaneous immune-related toxicity	58
The effects of Aurora Kinase inhibition on thyroid cancer growth and sensitivity to MAPK-directed therapies	58
In Vivo Pre-clinical characterization of a Novel Series of FGFR2 Selective Inhibitors with Potency Against Clinically Relevant Mutations	58
Standardization of viability assays and high-content live-cell imaging protocols for large-scale drug testing in prostate cancer PDX-derived organoids	58
Corrigendum to ‘Impact of immune checkpoint inhibitors and targeted therapy on health-related quality of life of people with stage III and IV melanoma: a mixed-methods systematic review [European Jour	55
Metabolic profile associated with chemoresistance in ovarian cancer cells using metabolomics	54
Neoadjuvant treatment for breast cancer patients in a Venezuelan breast center. Pathologic complete response: is it worth it?	54
Pagetoid Reticulosis, two case reports and review of the literature	53
Primary Cutaneous Marginal zone B-Cell lymphoma with lymph node involvement. Challenges in differential diagnosis and literature review	53
External validation and clinical utility assessment of PREDICT v2.2 prognostic model in young, node-negative, systemic treatment-naïve breast cancer patients	53
FOLFIRI with cetuximab or bevacizumab in RAS wild-type metastatic colorectal cancer: Refining first-line treatment selection by combining clinical parameters	52
Histologic Characterization of Sebaceous Glands in Cutaneous T-Cell Lymphoma: Diagnostic and Clinical Correlations	52
Impact of Oncotype DX Recurrence Score and Nottingham Prognostic Index on adjuvant treatment in patients with axillary lymph node micrometastasis in early breast cancer	52
Systematic evaluation of label-free protein quantification pipelines in 12 mouse syngeneic models	51
The role of a patient with breast cancer in a multidisciplinary team – from making a decision to changing the treatment option	51
Overcoming chemoresistance in triple negative breast cancer by bromodomain inhibition	51
Preoperative accelerated partial breast irradiation in locally recurrent breast cancer patients	51
Pharmacological activation of the mitochondrial stress protease OMA1 reveals a therapeutic liability in Diffuse Large B-Cell Lymphoma	49
TP53 mutations are frequently concurrent in patients with BRAF V600E mutated solid tumors and is associated with shorter duration of response to BRAF targeted therapy	49
Clinical and Experimental investigation of AKT1/2/3 isoforms indicated non-redundant isoform specific role in driving stemness and Cisplatin resistance in TNBCs	48
SNP rs10748643 within the promoter region of ENTPD1 (the gene encoding CD39) has no prognostic value in Sézary patients	46
Home based care for terminal cancer patients: study from rural part of India	46
Impact of establishing a genetic clinic in conjunction with clinical practice in India	46
Detecting actionable PIK3CA mutations through next-generation sequencing (NGS) in hormone receptor positive (HR+)/HER2-negative advanced/metastatic breast cancer (MBC): a real-life experience	46
T cell receptor beta constant 1 as a potential marker to better assess T cell clonality in skin samples	46
Contrast-enhanced mammography (CEM) with magnetic tracer as an alternative to MRI	45
Re: CARTIFAN-1: Concerning fatal adverse events with global use of chimeric antigen receptor–T-cell therapy in multiple myeloma	45
Survival after breast cancer in women with a subsequent live birth: Influence of age at diagnosis and interval to subsequent pregnancy	45
AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants	45
Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the randomized Phase II PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizum	45
Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1–49 %): TOPGAN2023-01	44
Smoking and immunotherapy efficacy in lung cancer by PDL1 subgroups: An individual participant data meta-analysis of atezolizumab clinical trials	44

300 (PB288): Combination of RAS(ON) Multi-Selective and G12D-Selective Inhibitors Improves Antitumor Activity and Enhances Antitumor Immunity in Preclinical Models of KRASG12D-Driven Cancers	44
Prognostic impact of the BRAF V600E mutation in patients with MSI-high metastatic colorectal cancer treated with immune checkpoint inhibitors	43
Absence of lobular carcinoma in situ is a poor prognostic marker in invasive lobular carcinoma	43
Proton pump inhibitors and antibiotics adversely effect the efficacy of nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck	43
CNS infections in patients with hematological or oncological diseases (including cellular therapies) – 2024 update of the guideline of the Infectious Diseases Working Party (AGIHO) of the German Socie	43
Sex-specific survival in advanced metastatic melanoma – a DeCOG study on 2032 patients of the multicenter prospective skin cancer registry ADOREG	43
Life-threatening skin reaction with Enfortumab Vedotin: Six cases	43
Perspectives on the role of “-Omics” in predicting response to immunotherapy	43
Quality indicators for systemic anticancer therapy services: a systematic review of metrics used to compare quality across healthcare facilities	43
Letter Re: Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS	43
Molecular diagnostics enables detection of actionable targets: the Pediatric Targeted Therapy 2.0 registry	43
A global phase II randomized trial comparing oral taxane ModraDoc006/r to intravenous docetaxel in metastatic castration resistant prostate cancer	43
STC-15, an oral small molecule inhibitor of the RNA methyltransferase METTL3, inhibits tumour growth through activation of anti-cancer immune responses associated with increased interferon signalling,	42
10 years or less of extended adjuvant endocrine therapy for postmenopausal breast cancer patients: A systematic review and network meta-analysis	42
Association of tumour burden with the efficacy of programmed cell death-1/programmed cell death ligand-1 inhibitors for treatment-naïve advanced non-small-cell lung cancer	41
A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patien	41
Total tumor volume predicts overall survival and response to induction chemotherapy in patients with colorectal cancer liver metastases: An ancillary study of the phase 3 CAIRO5 trial	41
Target Actionability Review: a systematic evaluation of replication stress as a therapeutic target for paediatric solid malignancies	40
Recent advances and future strategies in first-line treatment of ES-SCLC	40
Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS	40
Impact of pharmacodynamic biomarkers in immuno-oncology phase 1 clinical trials	39
Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: Pooled analysis of the CAO/ARO/AIO-12 and the OPRA randomized phase 2 tr	39
Patient-led follow-up after curative colorectal cancer surgery: The primary outcome analysis of the prospective, multicentre FUTURE-primary implementation study	39
Ibrutinib-related skin cancer: A pharmacovigilance study from the Food and Drug Administration Adverse Event Reporting System	39
Comparative efficacy of immunotherapy-based treatment versus chemotherapy-only in patients with unresectable NSCLC with disease progression post chemoradiation and durvalumab	39
Letter Re: Impact of early discontinuation of adjuvant endocrine therapy on survival in breast cancer: A target trial emulation	38
First-line pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: Health-related quality of life from the randomized phase III KEYNOTE-859 tria	38
Surgical stage in the era of molecular profiling of endometrial cancer	38
A population-based study describing characteristics, survival and the effect of TKI treatment on patients with EGFR mutated stage IV NSCLC in the Netherlands	38
Limited impact of real-world evidence in medical oncology: How can AI turn the tide	38
Trastuzumab emtansine for patients with non–small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations	37
Early versus late response to PD-1-based immunotherapy in metastatic melanoma	37
A first-in-human, phase 1a dose-escalation study of the selective MEK1/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanoma	37
Defining the role of real-world data in cancer clinical research: The position of the European Organisation for Research and Treatment of Cancer	37
Lurbinectedin shows clinical activity and immune-modulatory functions in patients with pre-treated small cell lung cancer and malignant pleural mesothelioma	37
Immunotherapy for brain metastases and primary brain tumors	36
Pembrolizumab for previously treated, microsatellite instability–high/mismatch repair–deficient advanced colorectal cancer: final analysis of KEYNOTE-164	36
Clinical trial inclusion in patients with relapsed/refractory neuroblastoma following the European Precision Cancer Medicine trial MAPPYACTS	36
Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life	36
Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer	36
A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma	36
443 (PB431): A Sub Analysis of Clinical Study of Tomaralimab, a Toll-like Receptor 2 (TLR-2) Antibody, in Patients with Lower Risk Myelodysplastic Syndromes (MDS) That Have Received Prior Hypomethylat	35
The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases – A multicenter cohort study	35
344 (PB332): Systematic assessment of ALC1 depletion as a therapeutic approach in homologous recombination deficient cells	35
DNA methylation markers in the detection of hepatocellular carcinoma	35
299 (PB287): Lomitapide enhances cytotoxic effects of temozolomide in chemoresistant glioblastoma	34
A-206 4 cases of pediatrics mycosis fungoides revealed by recalcitrant psoriatic palmoplantar keratoderma	34
158 (PB146): Immune Monitoring in Preclinical Tumor Mouse Models Using Spectral Analyzer Technology	34
Peer Review Policy for the European Journal of Cancer (EJC)	34
43 (PB031): MBT-C101, a first-in-class, selective, and potent HSP90 chaperonemediated degrader of PI3Ka	34
26 (PB014): Development of Tumour-specific CD146 CAR-T Cells for Targeted Cancer Immunotherapy of Solid Tumours	34
Organ-specific tumor dynamics predict survival of patients with metastatic colorectal cancer	33
Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme	33
Temporal changes in survival among adult patients with acute lymphoblastic leukaemia diagnosed in the period 1998-2020 – A Danish nationwide population-based cohort study	33
A-170 Is there microbial dysbiosis in CTCL? A pilot study	33
Atypical B cells (CD21-CD27-IgD-) correlate with lack of response to checkpoint inhibitor therapy in NSCLC	33
First-line encorafenib plus binimetinib and pembrolizumab for advanced BRAF V600-mutant melanoma: Safety lead-in results from the randomized phase III STARBOARD study	33
Norwegian general population normative data for the European Organization for Research and Treatment of Cancer questionnaires: the Quality of Life Questionnaire-Core 30, the Sexual Health Questionnair	33
Cisplatin shortage results in substitution of more expensive treatments: Drug cost analysis	33
Nivolumab plus ipilimumab with chemotherapy for non–small cell lung cancer with untreated brain metastases: A multicenter single-arm phase 2 trial (NIke, LOGiK 2004)	33
Q-TWiST analysis of pembrolizumab combined with chemotherapy as first-line treatment of metastatic triple-negative breast cancer that expresses PD-L1	33
Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas	33
A-186 Molecular Insights into Primary Cutaneous CD30+ T-cell Lymphoproliferative Disorders: Wnt/Beta-Catenin Pathway Activation and Prognostic Role of TP53 mutations?	33
Nazartinib for treatment-naive EGFR-mutant non−small cell lung cancer: Results of a phase 2, single-arm, open-label study	32
HER2 amplification in colorectal cancer with brain metastasis: A propensity score matching study	32
Effects of capecitabine as part of neo-/adjuvant chemotherapy – A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients	32
Impact of EDP-M on survival of patients with metastatic adrenocortical carcinoma: A population-based study	32
MBD4 deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patients	32
Prognosis of early-onset versus late-onset sporadic colorectal cancer: Systematic review and meta-analysis	31
A novel computational pathology approach for identifying gene signatures prognostic of disease-free survival for papillary thyroid carcinomas	31
Performance status eligibility requirements and enrollment characteristics in cancer clinical trials leading to US Food and Drug Administration drugs approval (2009–2023)	31
Phase 1b/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases	31
Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer	31
294 (PB282): Suppression of Glioblastoma Progression by FDA-Approved Central Nervous System-Accumulating Drugs via Autophagy Modulation and ER Stress-Induced Apoptosis	30
100 (PB088): KRASmulti inhibitor BI 3706674 shows efficacy in KRAS-driven preclinical models of cancer that supports clinical testing in patients with tumors harboring KRASG12V mutations and KRAS wild	30
Survival and patient-reported outcomes of real-world high-risk stage II and stage III colon cancer patients after reduction of adjuvant CAPOX duration from 6 to 3 months	30
Anthropometric indicators of adiposity and risk of primary liver cancer: A systematic review and dose–response meta-analysis	30
444 (PB432): First-in-human phase 1 study of RGT-264, a potent hematopoietic progenitor kinase 1 (HPK1) inhibitor in patients (pts) with advanced solid tumors	30
237 (PB225): Targeting NOS sensitizes the NRAS-mutant melanomas to MEK inhibition and induces Immunogenic Cell Death	30
5 Oral: Preliminary Results from a Phase Ia/Ib, Open-label, Multicenter Study of ZL-1310, a DLL3-targeted ADC, to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects with Small Cell Lu	30

146 (PB134): First disclosure of AZD3470, a highly potent MTA-cooperative PRMT5 inhibitor in PRIMROSE and PRIMAVERA clinical studies	30
121 (PB109): TT125-802, a highly selective bromodomain inhibitor of CBP/p300, in patients with advanced solid tumors: an update on the phase I study	30
Predictive value of BRCA1/RAD51C methylation in HGSOC – An ancillary study of the PAOLA-1/ENGOT-ov25 phase 3 trial	30
An International Registry Study of Early-Stage NSCLC treatment variations (LUCAEUROPE) in Europe and the USA highlighting variations	30
Contrast enhanced mammography in further assessment of screen-detected breast cancer	29
Loss of RHOA impairs lenalidomide antitumor activity in mantle cell lymphoma	29
Title Page	29
ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA	29
Reliability of patient-reported toxicities during adjuvant chemotherapy	29
External validation and clinical utility assessment of PREDICT breast cancer prognostic model in young, systemic treatment-naïve women with node-negative breast cancer	29
ERBB2 mRNA expression in HER2-low breast cancer	29
Mogamulizumab in patients with mycosis fungoides or Sézary syndrome: interim analysis of the German non-interventional MINT study	29
Real-life evaluation of efficacy and tolerability of chlormethine gel in Italian centers	29
Editorial Board	29
Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for TTF-1 negative advanced nonsquamous non–small cell lung cancer: A multicenter, single-arm phase 2 trial (F1NE TUNE, LOGiK 2102	29
Photodynamic therapy for the treatment of primary cutaneous B-cell marginal zone lymphoma: a series of 4 patients	29
Racial disparity and time to treatment initiation effects on survival differences in breast cancer: a DAGs-based review protocol for a systematic review of cohort studies	29
Lineage-specific regulation of PD-1 expression in early-stage hepatocellular carcinoma following 90yttrium transarterial radioembolization – Implications in treatment outcomes	29
Pandemic driven preoperative moderate hypofractionated radiotherapy for soft tissue sarcomas	29
A-153 Primary cutaneous T-cell lymphoma not otherwise specified (NOS) uncovering a novel RAB27A variant in Griscelli syndrome type 2	29
Why effect sizes are systematically larger for progression-free survival than overall survival in cancer drug trials: Prognostic scores as a way forward	29
Mode of Recurrence/ Metastasis Detection in Breast cancer survivors	28
First xenograft and cell line of primary cutaneous diffuse large B-cell lymphoma, leg type	28
Is there microbial dysbiosis in CTCL? A pilot study	28
Multimodal therapy with bexarotene and extracorporeal photopheresis for T-cell cutaneous lymphomas: real-life experiences in Argentina	28
Contrast Enhanced Mammography in Breast Cancer Surveillance	28
Placing the patient at the heart of discovery science	28
Triple-negative breast cancer cells that survive ionizing radiation exhibit an Axl-dependent aggressive radioresistant phenotype	28
Letter re: Reduced-dose radiotherapy for Epstein-Barr virus DNA selected staged III nasopharyngeal carcinoma: A single-arm, phase 2 trial	28
Real-time drug testing of paediatric diffuse midline glioma to support clinical decision making: The Zurich DIPG/DMG centre experience	27
Peripheral blood neutrophil/lymphocyte ratio as a prognostic factor in triple negative breast cancer	27
Editorial Board	27
CABA-V7: a prospective biomarker selected trial of cabazitaxel treatment in AR-V7 positive prostate cancer patients	27
Primary cutaneous follicle center lymphoma with secondary systemic evolution	27
HX301, a potent CSF1R inhibitor, suppresses tumor associated M2 macrophage (TAM), enhancing tumor immunity and causing transit tumor inhibition in syngeneic EMT-6 tumors	27
A multidisciplinary approach to the enhancement of quality of life of breast cancer patients in the South-west, Nigeria	27
Initial experience with targeted axillary dissection (TAD) guided by ultrasound in early-stage node positive breast cancer patients undergoing upfront surgery	26
A phase II study to evaluate the efficacy of regorafenib in C-KIT mutated metastatic malignant melanoma patients who have progressed on first-line treatment: A Multicenter Trial of Korean Cancer Study	26
Targeted axillary dissection or sentinel node biopsy after neo-adjuvant treatment in clinically node positive patients – the West of Scotland experience	26
Measuring variation in the quality of systemic anti-cancer therapy delivery across hospitals: A national population-based evaluation	26
Homologous recombination deficiency in ovarian cancer: Global expert consensus on testing and a comparison of companion diagnostics	26
Symptom burden and health-related quality of life in patients with Mycosis Fungoides and Sezary Syndrome: findings from the International PROSPER study	26
Ocular, meningeal and cerebral involvement of mycosis fungoides associated with an immunophenotypic switch from CD4+ to CD8+	26
Transcriptomic landscape of primary cutaneous diffuse large B-cell lymphoma, leg type reveals novel therapeutic clues	26
MYC inhibition by Omomyc unveils a prognostic gene signature in Melanoma	26
The microbiome of patients with breast cancer; observational study on the microbiome composition of breast cancer patients and the effects of chemotherapy treatment on the microbiome	26
A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered dise	26
Integrated Spatial and Single-Cell Profiling Uncovers Stage-Specific Immune Remodeling in Mycosis Fungoides	26
Efficacy and safety of abemaciclib in the treatment of HR+ HER2-advanced breast cancer: real world data	26
Characteristics and clinical outcomes of breast cancer patients under different modalities of breast-conserving surgery and lymph node management in China	26
Characterisation of adaptive responses of cancer cells to oxaliplatin by analysis of leading edge genes from genes set enrichment analysis	26
Regulation of oncogenic transcription and tumor growth in pediatric cancers by the CDK9 inhibitor KB-0742	26
Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trial	26
Response to letter Re: Critical evaluation of sentinel lymph node biopsy in pT1b and pT2a melanoma patients: A nationwide population-based study	26
Clinical and Morphological Determinants of Health-Related Quality of Life in Mycosis Fungoides and Sézary Syndrome: Updated Results from the PROCLIPI Study	26
Brentuximab vedotin retreatment in patients with cutaneous T-cell lymphoma: a pooled analysis of real-world studies	25
Circulating tumour DNA to augment PET-CT in determining clinical outcome after head and neck cancer treatment	25
Association of tumor-infiltrating lymphocytes with recurrence score in hormone receptor-positive/HER2-negative breast cancer: Analysis of four prospective studies	25
Computerizing the first step of the two-step algorithm in dermoscopy: A convolutional neural network for differentiating melanocytic from non-melanocytic skin lesions	25
Nivolumab induces long-term remission in a patient with fusariosis	25
Cutaneous T-Cell lymphomas and nEDD (nonsyndromic epidermal differentiation disorders) associated with a novel NIPAL4 variant: 3 cases	25
Are all mismatch repair deficient endometrial cancers created equal? A large, retrospective, tertiary center experience	25
Systematic nutritional screening and assessment in older patients: Rationale for its integration into oncology practice	25
Quality of life in cutaneous lymphoma varies by lymphoma type	25
Skin melanoma survival is improving in Europe but regional differences persist: Results of the EUROCARE-6 study	25
Corrigendum to “International expert consensus on the clinical integration of circulating tumor cells in solid tumors” [Eur. J. Cancer 231 (2025) 116050]	25
Durable time to next treatment of CTCL using low dose TSEBT: An effective therapy with durable responses	25
A-200 Mogamulizumab in patients with mycosis fungoides or Sézary syndrome: Update on the German non-interventional MINT study	25
High serum LDH and liver metastases are the dominant predictors of primary cancer resistance to anti-PD(L)1 immunotherapy	25
Combined immunotherapy in melanoma patients with brain metastases: A multicenter international study	25
Letrozole to prevent breast cancer in postmenopausal women with BRCA1/2 mutations (LIBER study)	25
A Case Series of Five Patients Diagnosed with Mycosis Fungoides in Childhood	25
Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer—findings from the RIBECCA trial	24
Editorial Board	24
Unraveling the clinical impact of differential DNA methylation in PDAC: A systematic review	24
Survival and immunotoxicities in association with sex-specific body composition patterns of cancer patients undergoing immune-checkpoint inhibitor therapy – A systematic review and meta-analysis	24
A-218 New histopathologic patterns of Mogamulizumab-associated rash and a revision of already described histopathologic findings	24
First-in-man, first-in-class phase I study with the monopolar spindle 1 kinase inhibitor S81694 administered intravenously in adult patients with advanced, metastatic solid tumours	24
Epithelioid hemangio-endothelioma (EHE) in NETSARC: The nationwide series of 267 patients over 12 years	24
Germline NGS targeted analysis in adult patients with sporadic adrenocortical carcinoma	24
CAR-T cell therapy for patients with extramedullary multiple myeloma：Opportunities and challenges	24
Phase I dose-escalation study of the pan-PI3 K inhibitor copanlisib in children and adolescents with relapsed/refractory solid tumors	24
A machine learning tool for identifying non-metastatic colorectal cancer in primary care	24
Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders’ Collaborative Consortium (EORTC 1419)	24
Editorial Board	24
Omicron variant: A clear and present danger for patients with cancer	24
Proof of concept and design of an externally controlled trial for patients with gastro-enteropancreatic neuroendocrine carcinomas based on the randomized phase II BEVANEC trial	24
32 (PB020): Discovery of novel MTA-cooperative PRMT5 inhibitors as targeted therapeutics for MTAP-deleted cancers	23
454 (PB442): Cross-HLA targeting of synthetic neoepitopes with T cell engagers to eradicate KRAS-G12C inhibitor-resistant cancers	23
88 (PB076): Obesity reveals potential therapeutic targets in adipocyte- derived extracellular vesicles of gastric cancer patients	23
149 (PB137): Dual metastasis- and tumor-inhibitory efficacy of a first-in-class metastasis-initiating-cell-targeted therapeutic antibody	23
134 (PB122): ERAS-801: a selective brain-penetrant EGFR inhibitor with improved activity against EGFR extracellular domain-mutant glioblastoma	23
365 (PB353): Targeting fibroblast activation protein to improve immunotherapy efficacy in head and neck squamous cell carcinoma	23
284 (PB272): Enhancing Biobank Quality Control: An NGS-QC-PANEL as a Superior Alternative to STR Assays for Large-Scale Sample Authentication	23
Title Page	23